Citizens Jmp cut shares of Allakos (NASDAQ:ALLK – Free Report) from a strong-buy rating to a hold rating in a research note published on Monday,Zacks.com reports. Allakos Price Performance NASDAQ ALLK ...

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

Leerink Partners analyst Thomas Smith has reiterated their neutral stance on ALLK stock, giving a Hold rating on January 27.Invest with ...

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

A Bay Area biotech firm is laying off 75% of its staff following a flopped clinical trial. Allakos, based in San Carlos, ...

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Hold rating on Allakos (ALLK – Research Report), with a price ...

California, USA-based biotech Allakos saw its shares plummet 78.8% to $0.26 yesterday, after it announced disappointing ...

Allakos, Bay Area biotech firm based in San Carlos, is laying off 75% of its staff and eyeing a shutdown after its clinical ...

It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...

Allakos, Inc. shares lost more than three-quarters of its market capitalization on Tuesday afternoon, marking a record low ...